Tierra Biosciences has secured $11.4 million in a Series A funding round led by Material Impact. This investment aims to enhance its protein engineering platform that leverages predictive AI for protein production.
Differing from generative AI, Tierra uses predictive AI to analyze patterns in large datasets for outcome predictions, combined with language models and cell-free platforms to create proteins beyond natural limitations.
With this funding, Tierra, a US-based company active in early-stage drug development, plans to expand its partnerships beyond the pharmaceutical sector, reaching into industrial and agricultural markets.
The company’s technology promises to streamline the traditionally slow and inefficient process of protein engineering, offering rapid production of custom proteins for discovery purposes. This advancement is part of a broader trend of integrating AI into drug development, a move also being embraced by major pharmaceutical companies.
